We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

New Gene Therapy Opportunities for Retinal Dystrophy

New Gene Therapy Opportunities for Retinal Dystrophy

New Gene Therapy Opportunities for Retinal Dystrophy

New Gene Therapy Opportunities for Retinal Dystrophy

Credit: Arteum.ro on Unsplash.
Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "New Gene Therapy Opportunities for Retinal Dystrophy"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

New opportunities towards gene therapy and diagnosis for the blinding eye disease, retinal dystrophy, may now become available following work done by the Eye Genetics Research Unit at Children’s Medical Research Institute.

This work was published in the Journal of Personalized Medicine.

The team looked at the RPGR gene which is involved in maintaining healthy photoreceptor cells. Variants in this gene are the main contributor to eye disease such as rod cone dystrophy and gene therapy for this condition is now in clinical trials.

Rod cone dystrophy affects rod and cone photoreceptor cells and manifests in decreased night and peripheral vision and progressive vision loss. There are more than 60 identified contributing disease genes.

CMRI’s Eye Genetics team investigated a novel genetic variant in the RPGR gene in a patient who has rod cone dystrophy and, working alongside CMRI’s Stem Cell Medicine team, used induced pluripotent stem cells to produce retinal organoids. This work found that the novel variant impacted the function of the gene.

Head of CMRI’s Eye Genetics Research Unit, Professor Robyn Jamieson said the first and second authors Fidelle Karam and To Ha Loi had put in tremendous work to show that this genetic variant was disease-causing, and they had now identified biomarkers to further investigate novel therapies directed at variants in the RPGR gene.

“There is potential for clinical trials in the future for genetic therapies related to disease caused by variants in RPGR, so this work provides a genetic diagnosis, as well as avenues for investigation and biomarkers for investigation of new therapies for people with variants in this gene – which is one of the most common causes of retinal dystrophy.”

Reference: Chahine Karam F, Loi TH, Ma A, et al. Human iPSC-derived retinal organoids and retinal pigment epithelium for novel intronic RPGR variant assessment for therapy suitability. J.Pers. Med. 2022;12(3). doi: 10.3390/jpm12030502.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.